Search results for "biochemical recurrence"

showing 7 items of 17 documents

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Metronomic cyclophosphamide induces regulatory T cells depletion and PSA‐specific T cells reactivation in patients with biochemical recurrent prostat…

2019

Biochemical recurrence (BCR) occurs in up to 40% of prostate cancer patients after prostatectomy. In our study, we performed an immune monitoring study in 20 prostate cancer patients with BCR previously treated with metronomic cyclophosphamide (mCTX). We observed a decrease of regulatory T cells (Tregs) from 2 months and this was more pronounced after 6 months of mCTX treatment. This drop of Tregs was associated with increased level of activated HLADR+ CD45R0+ T cells in peripheral blood. Furthermore, a reactivation of Th1 polarized anti-PSA T-cell response was detected in BCR patients treated with mCTX. However, dendritic cell subsets counts and activation were not influenced by the treatm…

MaleBiochemical recurrenceCancer ResearchT-Lymphocytesmedicine.medical_treatmentLymphocyte ActivationT-Lymphocytes RegulatoryLymphocyte DepletionAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicinemedicineHumansAntineoplastic Agents AlkylatingCyclophosphamideMetronomic cyclophosphamideDiminutionProstatectomybusiness.industrybreakpoint cluster regionProstatic NeoplasmsDendritic cellProstate-Specific Antigenmedicine.diseaseOncology030220 oncology & carcinogenesisAdministration MetronomicCancer researchNeoplasm Recurrence LocalbusinessInternational Journal of Cancer
researchProduct

Cell-Free Circulating Plasma hTERT mRNA Is a Useful Marker for Prostate Cancer Diagnosis and Is Associated with Poor Prognosis Tumor Characteristics

2012

BackgroundSerum prostate-specific antigen (PSA) is the most widely used marker for diagnosing prostate cancer (PCa). It lacks specificity and predictive value, resulting in inaccurate diagnoses and overtreatment of the disease. The aim of this study was to assess the usefulness of plasma telomerase reverse transcriptase (hTERT) mRNA as a diagnostic and prognostic tool for PCa and its association with clinicopathological parameters of tumors.Principal findingsPlasma hTERT mRNA levels were determined by qRT-PCR in 105 consecutive patients with elevated PSA levels and in 68 healthy volunteers. The diagnostic accuracy, the efficacy as a prognostic factor of biochemical recurrence and the associ…

MaleBiochemical recurrenceOncologymedicine.medical_specialtyPathologyUrologyScienceProstate cancerDiagnostic MedicineInternal medicineBlood plasmaBiopsyBiomarkers TumorPathologyCancer Detection and DiagnosisEarly DetectionHumansMedicineTelomerase reverse transcriptaseRNA MessengerTelomeraseAgedBenign Prostatic HyperplasiaTumor markerAged 80 and overClinical ChemistryUnivariate analysisMultidisciplinarymedicine.diagnostic_testbusiness.industryProstate CancerQProstate DiseasesRProstatic NeoplasmsMiddle AgedPrognosismedicine.diseaseClinical Laboratory SciencesOncologyMedicineBiomarker (medicine)businessBiomarkersCancer ScreeningResearch ArticleGeneral PathologyPLoS ONE
researchProduct

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

2012

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.Plasma telomerase reverse transcriptase (hTERT) mRNA levels were determined by qRT-PCR in 49 patients with localized and locally advanced PCa. Diagnostic accuracy and efficacy as a prognostic factor of biochemical recurrence of plasma hTERT…

MaleOncologyBiochemical recurrencemedicine.medical_specialtyPathologyTelomeraseClinical BiochemistryProstate cancerAntigenRecurrenceInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansTelomerase reverse transcriptaseRNA MessengerOverdiagnosisTelomeraseAgedNeoplasm StagingPharmacologybusiness.industryProstatic NeoplasmsMiddle Agedmedicine.diseaseROC CurveArea Under CurveLocalized diseaseLocally advanced diseasebusinessExpert Opinion on Biological Therapy
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.

2020

Abstract Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients. Evidence acquisition A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Re…

OncologyBiochemical recurrenceMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyContext (language use)PelvisAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicinePositive nodesInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)ProstatectomyProstate cancerbusiness.industryProstatectomyLymph node; Positive nodes; Prostate cancer; Radical prostatectomyProstatic Neoplasmsmedicine.diseaseRadical prostatectomyRadiation therapySystematic reviewOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionSurgeryLymph nodebusinessEuropean urology oncology
researchProduct

Diagnostic efficacy of Gallium-68-PSMA PET/CT in 565 patients with biochemical recurrence of prostate cancer

2019

OncologyBiochemical recurrencemedicine.medical_specialtyProstate cancerchemistrybusiness.industryInternal medicineMedicinechemistry.chemical_elementGalliumbusinessmedicine.diseasePsma pet ct57. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct